About Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare liver diseases. The company aims to address significant unmet medical needs through its pipeline of novel therapeutic candidates, leveraging its expertise in drug discovery and development. Mirum's commitment to advancing patient care is evident in its efforts to deliver effective solutions that improve the quality of life for individuals suffering from conditions related to liver dysfunction. Through rigorous research and clinical studies, Mirum strives to contribute to the advancements in treatments that target these often overlooked diseases. Read More
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,820 shares of common stock and 5,390 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced in the second quarter of 2026.
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 14,460 shares of common stock and 7,220 restricted stock units (“RSUs”) to two new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC).
